Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 18, 2022

SELL
$22.17 - $51.8 $17,979 - $42,009
-811 Reduced 1.08%
73,965 $3.82 Million
Q2 2022

Aug 15, 2022

BUY
$15.36 - $27.51 $151,618 - $271,551
9,871 Added 15.21%
74,776 $1.85 Million
Q1 2022

May 16, 2022

SELL
$22.22 - $39.12 $129,320 - $227,678
-5,820 Reduced 8.23%
64,905 $1.63 Million
Q4 2021

Feb 15, 2022

BUY
$18.38 - $40.5 $29,922 - $65,934
1,628 Added 2.36%
70,725 $2.58 Million
Q3 2021

Nov 15, 2021

SELL
$13.18 - $19.83 $126,488 - $190,308
-9,597 Reduced 12.2%
69,097 $1.18 Million
Q2 2021

Aug 16, 2021

SELL
$9.59 - $50.88 $3,318 - $17,604
-346 Reduced 0.44%
78,694 $1.05 Million
Q1 2021

May 18, 2021

SELL
$49.53 - $68.4 $10,450 - $14,432
-211 Reduced 0.27%
79,040 $4.05 Million
Q4 2020

Feb 16, 2021

SELL
$47.25 - $65.16 $1,464 - $2,019
-31 Reduced 0.04%
79,251 $4.91 Million
Q3 2020

Nov 17, 2020

BUY
$46.35 - $61.69 $566,489 - $753,975
12,222 Added 18.23%
79,282 $4.35 Million
Q2 2020

Aug 17, 2020

BUY
$38.58 - $65.07 $198,185 - $334,264
5,137 Added 8.3%
67,060 $3.86 Million
Q1 2020

May 13, 2020

SELL
$32.73 - $50.78 $10,048 - $15,589
-307 Reduced 0.49%
61,923 $2.49 Million
Q4 2019

Feb 14, 2020

SELL
$6.81 - $39.55 $3,398 - $19,735
-499 Reduced 0.8%
62,230 $2.46 Million
Q2 2019

Aug 14, 2019

BUY
$8.31 - $14.85 $228,392 - $408,137
27,484 Added 77.98%
62,729 $583,000
Q4 2018

Feb 13, 2019

BUY
$9.15 - $12.26 $7,914 - $10,604
865 Added 2.52%
35,245 $385,000
Q3 2018

Nov 14, 2018

BUY
$10.49 - $13.72 $8,780 - $11,483
837 Added 2.5%
34,380 $435,000
Q2 2018

Aug 14, 2018

SELL
$10.62 - $13.98 $49,329 - $64,937
-4,645 Reduced 12.16%
33,543 $442,000
Q1 2018

May 15, 2018

SELL
$5.9 - $14.99 $4,501 - $11,437
-763 Reduced 1.96%
38,188 $519,000
Q4 2017

Feb 14, 2018

BUY
$5.53 - $8.42 $4,805 - $7,316
869 Added 2.28%
38,951 $232,000
Q3 2017

Nov 13, 2017

BUY
$6.5 - $10.69 $247,533 - $407,096
38,082
38,082 $283,000

Others Institutions Holding CCXI

About ChemoCentryx, Inc.


  • Ticker CCXI
  • Exchange NASDAQ
  • Shares Outstandng 71,919,696
  • Market Cap $3.68M
  • Description
  • ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil...
More about CCXI
Track This Portfolio

Track California State Teachers Retirement System Portfolio

Follow California State Teachers Retirement System and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of California State Teachers Retirement System, based on Form 13F filings with the SEC.

News

Stay updated on California State Teachers Retirement System with notifications on news.